Important Dates

no event

Latest News

GENERATION HD2 to continue

On 17 April 2025, Roche released a community letter announcing that GENERATION HD2 will continue following planned interim analysis by the independent Data Monitoring Committee. Enrollment has completed for this randomised, double-blind study of tominersen, but participants on the 60 mg dose will move to the higher dose (100 mg every 16 weeks), given the […]

Read More…

EHDN Newsletter – 54th edition

The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]

Read More…

Clinical Trial Update: uniQure alignment with FDA on path forward for AMT-130 in HD

Clinical Trial Update: On 10th December, uniQure shared the exciting news about alignment with the US Food and Drug Administration (FDA) on a path forward for AMT-130 gene therapy in Huntington’s disease. The FDA agreed that the basis for a Biologics License Application for Accelerated Approval of AMT-130 may include: 1. Data from ongoing phase […]

Read More…

EHDN/MDS (ES) Fellowship programme now open for applications

The main objective of the fellowship programme is to motivate and facilitate the training of young professionals (neurologists, psychiatrists, psychologists, physiotherapists, clinical geneticists or other healthcare professionals) working in HD clinical practice through the sharing of knowledge and experience. For more information please read the fellowship programme page. […]

Read More…